Empagliflozin attenuates cardiac fibrosis in diabetic mice11 and preserves myocardial function in a mouse model of pressure overload-induced heart failure.12 Canagliflozin activates AMP kinase (AMPK), whose cardioprotective effects are well established, by inhibiting mitochondrial function and increasing cellular AMP levels in vitro. 13 However, several aspects of the direct effects of SGLT2 inhibition on the human heart remain unclear.14 This evidence concerns the gene SLC5A2 and heart failure.